Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Professor Irina Udalova on her successful Wellcome Trust Investigator Award entitled “Molecular control of pathogenic neutrophil responses in inflammation”.

Irina has been awarded £1.5 million over 5 years to research how neutrophil function in the tissue is guided by intrinsic molecular regulators and influenced by extrinsic protein and lipid signals produced by macrophages. Recent work has highlighted a number of factors that will be functionally validated and the hypothesis that neutrophil accumulation and activity in tissues during sterile inflammation is controlled by resident and effector macrophages will be examined. Understanding the control of pathogenic neutrophil responses and identification of key regulators will help to redefine these understudied cells in chronic inflammatory disorders such as such as rheumatoid arthritis, atherosclerosis, diabetes  amongst others and may lead to new treatments reducing the burden of human chronic inflammatory disease.

Speaking of the award, Professor Udalova stated “I am delighted to receive this award as the recognition of our unique expertise in neutrophil genomics, recently developed cutting edge technologies and established key strategic collaborations. I believe our work in this extremely interesting and completely under-studied area of research in neutrophil biology will lead to important and transforming discoveries”.

The grant will start on the 1st February 2018.

Similar stories

Dr Alex Clarke wins Emerging Leaders Prize for lupus research

Alex is one of three exceptional lupus researchers that have been announced as winners of the Medical Research Foundation’s sixth Emerging Leaders Prize.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.

Study reveals new evidence on rare blood-clotting condition after covid-19 vaccination

Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.

NDORMS contributes to new UK research to tackle monkeypox outbreak

The UK’s efforts to tackle the monkeypox outbreak will receive a huge boost with the creation of a new research consortium and a new study to study vaccine effectiveness.

World Osteoporosis Day 2022

A bone-healthy lifestyle is vital for strong bones and a mobile, fracture-free future. On World Osteoporosis Day, we are sharing advice from the International Osteoporosis Foundation (IOF), on putting your bone health first.